May 6, 2016 | 12:30 p.m. - 4:30 p.m. | San Diego, California
San Diego Convention Center
Program Chair: Michael J. Kennelly, MD

All Sessions located in Room 20D, unless otherwise noted. Programming is subject to change.

FRIDAY, MAY 6, 2016

12:30 p.m. - 12:35 p.m. Welcome and Introduction
Speaker: Michael J. Kennelly, MD

12:35 p.m. - 12:50 p.m. State-of-the-Art: Transitional Urologic Care: Effective Transition from Pediatric to Adult Urology
Speaker: Hadley M. Wood, MD

12:50 p.m. - 1:00 p.m. Updated Neuro-Urology Terminology & Classification of Neurogenic Lower Urinary Tract Dysfunction
Speaker: Jerzy B. Gajewski, MD

Detrusor Underactivity
Moderator: Alan J. Wein, MD
1:00 p.m. - 1:20 p.m. State-of-the-Art: Pathophysiology Of Detrusor Underactivity
Speaker: Christopher R. Chapple, BSc, MD, FRCS, FEBU
Challenging Case: Diabetic Male with LUTS and Hypocontractile Bladder

1:20 p.m. - 1:50 p.m. Panel Discussion & Difficult Case Presentation: Modern Treatment of Neurogenic Detrusor Underactivity
Conservative and Medical Therapy
Speaker: Michael B. Chancellor, MD
Lumbar to Sacral Nerve Rerouting
Speaker: Kenneth M. Peters, MD
Electrical Stimulation/Lattisimus Dorsi Treatment
Speaker: Karl-Dietrich Sievert, MD, PhD, FACS, FRCS
Discussion Q&A

Detrusor Overactivity
Moderator: Stephen R. Kraus, MD
1:50 p.m. - 2:00 p.m. State-of-the-Art: Pathophysiology of Neurogenic Detrusor Overactivity
Speaker: Toby C. Chai, MD
Challenging Case: Parkinson’s Male with NDO & BPO/RPH

2:00 p.m. - 2:40 p.m. Panel Discussion with Difficult Case Presentation: Contemporary Treatment of Neurogenic Detrusor Overactivity
New and Future Pharmacologic Strategies
Speaker: Karl-Erik Andersson, MD, PhD
Neurotoxin Therapy - Advantages and Disadvantages
Speaker: Sender Heschorn, MD, FRCSC
Bladder Reconstruction - Tissue Re-engineering
Speaker: David A. Ginsberg, MD
Discussion Q&A

Urethral Underactivity/Neurogenic Stress Incontinence
Moderator: Angelo E. Gousse, MD
2:40 p.m. - 3:00 p.m. Point-Counterpoint
Management of T11 SCI Male on CIC with SUI
Speaker: Craig V. Comiter, MD
Artificial Urinary Sphincter
Speaker: Timothy B. Boone, MD, PhD
Management of Tetraplegic Female with Non-Functional Urethra
Supravesical Urinary Diversion
Speaker: Una J. Lee, MD
Bladder Neck Closure and Urinary Diversion
Speaker: John C. Hairston, MD

Urethral Overactivity/Neurogenic Detrusor Sphincter Dyssynergia (DSD)
Moderator: John P. Lavelle, MB, FRCSI
3:00 p.m. - 3:40 p.m. Challenging Case: Tetraplegic Male with DSD
Panel Discussion with Difficult Case Presentation: Optimal Treatment of DSD in the Male Patient
Sphincter Stents
Speaker: Patrick J. Shenot, MD, FACS
Neurotoxins
Speaker: Christopher P. Smith, MD
Neurostimulation/Neuromodulation
Speaker: Graham H. Creasey, BSc, MB, ChB, FRCSEd
Suprapubic Tube
Speaker: Jerry G. Blaivas, MD
Discussion Q&A

Special Considerations in Neurologic Disorders
Moderator: Benjamin M. Brucker, MD
3:40 p.m. - 4:00 p.m. Sexual Dysfunction in Neurologic Disorders
Treatment of Neurologic Erectile and Female Sexual Dysfunction
Speaker: Stacy L. Elliott, MD
Autonomic Dysreflexia - Pathophysiology and Management
Speaker: Kristy M. Borawski, MD
Comparative Effectiveness of Bladder Management Strategies
Speaker: John T. Stoffel, MD
Neurogenic Bladder Surveillance
Speaker: Emmanuel Chartier-Kastler, AIHP, ACCA, FEBU

4:00 p.m. - 4:10 p.m. Sexual Dysfunction in Neurologic Disorders
Treatment of Neurologic Erectile and Female Sexual Dysfunction
Speaker: Stacy L. Elliott, MD
Autonomic Dysreflexia - Pathophysiology and Management
Speaker: Kristy M. Borawski, MD
Comparative Effectiveness of Bladder Management Strategies
Speaker: John T. Stoffel, MD
Neurogenic Bladder Surveillance
Speaker: Emmanuel Chartier-Kastler, AIHP, ACCA, FEBU

4:10 p.m. - 4:20 p.m. Sexual Dysfunction in Neurologic Disorders
Treatment of Neurologic Erectile and Female Sexual Dysfunction
Speaker: Stacy L. Elliott, MD
Autonomic Dysreflexia - Pathophysiology and Management
Speaker: Kristy M. Borawski, MD
Comparative Effectiveness of Bladder Management Strategies
Speaker: John T. Stoffel, MD
Neurogenic Bladder Surveillance
Speaker: Emmanuel Chartier-Kastler, AIHP, ACCA, FEBU

4:20 p.m. - 4:30 p.m. Sexual Dysfunction in Neurologic Disorders
Treatment of Neurologic Erectile and Female Sexual Dysfunction
Speaker: Stacy L. Elliott, MD
Autonomic Dysreflexia - Pathophysiology and Management
Speaker: Kristy M. Borawski, MD
Comparative Effectiveness of Bladder Management Strategies
Speaker: John T. Stoffel, MD
Neurogenic Bladder Surveillance
Speaker: Emmanuel Chartier-Kastler, AIHP, ACCA, FEBU

4:30 p.m. Adjourn
Educational Needs
Neurogenic bladder (NGB) dysfunction is commonly seen in patients who have neurologic conditions, such as spinal cord injury, multiple sclerosis, Parkinson’s disease, and cerebrovascular accident/stroke. The complications of NGB dysfunction have significant medical, economic, and social impacts, yet its management remains suboptimal. In an effort to guide best clinical practices and optimal treatment strategies for NGB, this program will provide participants with evidence-based information on how to diagnose and treat patients with NGB dysfunction with state-of-the-art methods. Additionally, expert insights will be given on how members of a multidisciplinary care team can help reduce the burden of NGB dysfunction by integrating patient perspectives into treatment management plans.

Educational Objectives
At the conclusion of the SUFU at the AUA 2016 Annual Meeting, attendees should be able to:

1. Evaluate various management options for neurogenic bladder dysfunction, including evidence-based treatments and novel therapeutic approaches.
2. Formulate individualized management plans for the various types of NGB dysfunction that incorporate evidence on treatment efficacy, benefits, and drawbacks, as well as patient perspectives.
3. Explain the impact of patient considerations and satisfaction in the management of neurogenic bladder dysfunction.
4. Distinguish the roles, benefits, and risks of approved and emerging therapies for neurogenic bladder dysfunction.

AUA Accreditation Information

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-physician Health Professionals: The AUA is not accredited to offer credit for non-physician health professionals. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty

Off-label or Unapproved Use of Drugs or Devices: It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Consent to Use of Photographic Images: Attendance at or participation in AUA meetings and other activities constitutes an agreement by the registrant to AUA’s use and distribution (both now and in the future) of the attendee’s image or voice in photographs and electronic reproductions of such meetings and activities.

Audio, Video and Photographic Equipment: The use of audio, video and other photographic recording equipment by attendees is prohibited inside AUA meeting rooms.

Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance/Dietary Needs: The American Urological Association complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance or has any dietary restrictions, please see the registration desk.

Disclaimer Statement: Statements, opinions and results of studies contained in the program and abstracts are those of the presenters/authors and do not reflect the policy or position of SUFU, nor does SUFU provide any warranty as to their accuracy or reliability. Every effort has been made to faithfully reproduce the abstracts as submitted. However, no responsibility is assumed by the SUFU for any injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.